Display options
Cite
Pérez-Moreno P, Quezada-Meza C, Chavez-Almarza C, et al. Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells. Front Oncol. 2020;10:1004doi: 10.3389/fonc.2020.01004.
Pérez-Moreno, P., Quezada-Meza, C., Chavez-Almarza, C., Niechi, I., Silva-Pavez, E., Trigo-Hidalgo, C., Aguayo, F., Jara, L., Cáceres-Verschae, A., Varas-Godoy, M., Díaz, V. M., García de Herreros, A., Burzio, V. A., & Tapia, J. C. (2020). Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells. Frontiers in oncology, 101004. https://doi.org/10.3389/fonc.2020.01004
Pérez-Moreno, Pablo, et al. "Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells." Frontiers in oncology vol. 10 (2020): 1004. doi: https://doi.org/10.3389/fonc.2020.01004
Pérez-Moreno P, Quezada-Meza C, Chavez-Almarza C, Niechi I, Silva-Pavez E, Trigo-Hidalgo C, Aguayo F, Jara L, Cáceres-Verschae A, Varas-Godoy M, Díaz VM, García de Herreros A, Burzio VA, Tapia JC. Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells. Front Oncol. 2020 Jul 30;10:1004. doi: 10.3389/fonc.2020.01004. eCollection 2020. PMID: 32850305; PMCID: PMC7406796.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2020 Jul 30;10:1004. doi: 10.3389/fonc.2020.01004. eCollection 2020.

Phosphorylation of Endothelin-Converting Enzyme-1c at Serines 18 and 20 by CK2 Promotes Aggressiveness Traits in Colorectal Cancer Cells.

Frontiers in oncology

Pablo Pérez-Moreno, Camila Quezada-Meza, Cristopher Chavez-Almarza, Ignacio Niechi, Eduardo Silva-Pavez, César Trigo-Hidalgo, Francisco Aguayo, Lilian Jara, Albano Cáceres-Verschae, Manuel Varas-Godoy, Víctor M Díaz, Antonio García de Herreros, Verónica A Burzio, Julio C Tapia

Affiliations

  1. Programa de Biología Celular y Molecular, Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile.
  2. Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile.
  3. Center for Integrative Biology, Faculty of Sciences, Universidad Mayor, Santiago, Chile.
  4. Programa de Virología, Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile.
  5. Programa de Genética, Facultad de Medicina, ICBM, Universidad de Chile, Santiago, Chile.
  6. Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
  7. Unidad Asociada CSIC, Programa de Recerca en Cáncer, Departament de Ciéncies Experimentals i de la Salut, Institut Hospital del Mar d'Investigacions Médiques, Universitat Pompeu Fabra, Barcelona, Spain.
  8. Facultad de Ciencias de la Vida, Universidad Andrés Bello, Fundación Ciencia & Vida, Andes Biotechnologies SpA, Santiago, Chile.

PMID: 32850305 PMCID: PMC7406796 DOI: 10.3389/fonc.2020.01004

Abstract

Endothelin-converting enzyme-1 (ECE1) activates the endothelin-1 peptide, which upregulates pathways that are related to diverse hallmarks of cancer. ECE1 is expressed as four isoforms differing in their N-terminal domains. Protein kinase CK2 phosphorylates the N-terminus of isoform ECE1c, enhancing its stability and promoting invasiveness of colorectal cancer cells. However, the specific residues in ECE1c that are phosphorylated by CK2 and how this phosphorylation promotes invasiveness was unknown. Here we demonstrate that Ser-18 and Ser-20 are the

Copyright © 2020 Pérez-Moreno, Quezada-Meza, Chavez-Almarza, Niechi, Silva-Pavez, Trigo-Hidalgo, Aguayo, Jara, Cáceres-Verschae, Varas-Godoy, Díaz, García de Herreros, Burzio and Tapia.

Keywords: aggressiveness; biomarker; cancer prognosis; pharmacological inhibitor; phosphorylation; protein stability

References

  1. J Biol Chem. 2000 Aug 4;275(31):23790-7 - PubMed
  2. Nat Rev Cancer. 2013 Sep;13(9):637-51 - PubMed
  3. Biochem Biophys Res Commun. 2010 Jul 23;398(2):173-7 - PubMed
  4. Adv Drug Deliv Rev. 2011 Jul 18;63(8):610-5 - PubMed
  5. Gene. 2006 May 24;373:109-15 - PubMed
  6. Cancer Res. 2002 Nov 15;62(22):6770-8 - PubMed
  7. Br J Cancer. 2008 Oct 7;99(7):1114-20 - PubMed
  8. Int J Pept Res Ther. 2006 Sep;12(3):291-295 - PubMed
  9. Sci Signal. 2015 Apr 14;8(372):ra35 - PubMed
  10. Pharmacol Rev. 2016 Apr;68(2):357-418 - PubMed
  11. FEBS Lett. 2012 Jul 30;586(16):2212-7 - PubMed
  12. Biochem Biophys Res Commun. 2012 Oct 26;427(3):606-10 - PubMed
  13. Can J Physiol Pharmacol. 2010 Aug;88(8):850-4 - PubMed
  14. J Exp Clin Cancer Res. 2019 Jul 5;38(1):287 - PubMed
  15. Pigment Cell Melanoma Res. 2018 Jan;31(1):64-72 - PubMed
  16. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15079-84 - PubMed
  17. Biochim Biophys Acta. 2008 Jan;1784(1):33-47 - PubMed
  18. Pharmaceuticals (Basel). 2017 Jan 28;10(1): - PubMed
  19. J Cell Biochem. 2011 Nov;112(11):3167-75 - PubMed
  20. Cell Death Dis. 2019 Jan 25;10(2):73 - PubMed
  21. Mol Oncol. 2020 Feb;14(2):347-362 - PubMed
  22. FASEB J. 2003 Mar;17(3):349-68 - PubMed
  23. Oncotarget. 2015 Dec 15;6(40):42749-60 - PubMed
  24. Asian Pac J Cancer Prev. 2019 Jan 25;20(1):23-32 - PubMed
  25. PLoS One. 2011 Feb 17;6(2):e17193 - PubMed
  26. Mol Cell Biochem. 2011 Oct;356(1-2):127-32 - PubMed
  27. Mol Cell Biochem. 2001 Nov;227(1-2):153-65 - PubMed
  28. Biochim Biophys Acta. 2010 Mar;1804(3):499-504 - PubMed
  29. Cancer Lett. 2019 Jun 28;452:152-157 - PubMed
  30. Cell Signal. 2010 Nov;22(11):1615-25 - PubMed
  31. J Hypertens. 2003 Nov;21(11):2111-24 - PubMed
  32. J Cell Sci. 2019 Apr 4;132(7): - PubMed
  33. Pharmaceuticals (Basel). 2017 Mar 05;10(1): - PubMed
  34. J Mol Med (Berl). 2016 Dec;94(12):1313-1326 - PubMed
  35. J Cell Physiol. 2011 Jul;226(7):1953-9 - PubMed
  36. J Biol Chem. 2002 Nov 29;277(48):46355-63 - PubMed
  37. Cancer Res. 2008 Nov 15;68(22):9265-73 - PubMed
  38. PLoS One. 2017 Dec 4;12(12):e0188854 - PubMed
  39. Cancers (Basel). 2018 Aug 23;10(9): - PubMed
  40. Cancer Invest. 2007 Sep;25(6):427-34 - PubMed
  41. J Exp Clin Cancer Res. 2016 Jul 29;35(1):121 - PubMed
  42. Int J Cancer. 2011 Aug 1;129(3):586-98 - PubMed
  43. Oncotarget. 2014 Aug 15;5(15):6484-96 - PubMed

Publication Types